RxDoctor Payments Data

Kathleen Schwegler, PA

Physician Assistant · Federal Way, WANPI 1912308479

Payments from drug & device makers

$5,464in general payments, 2019–2025

Across 273 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Regeneron Healthcare Solutions, Inc.$527
  • Pfizer$458
  • Ardelyx, Inc.$451
  • Takeda Pharmaceuticals U.S.A., Inc.$394
  • Merck$223
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,37498%
  • Education$902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,464 in reported general payments places this provider in the 95th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$22,394
Medicare patients
218
Services billed
293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin17$50,830
LinzessLinaclotide45$45,823
Mesalamine34$21,882
MovantikNaloxegol Oxalate19$7,482
Dexlansoprazole DrDexlansoprazole19$6,964
MotegrityPrucalopride Succinate12$6,031
Budesonide EcBudesonide19$4,814
Pantoprazole Sodium231$3,787
Lubiprostone13$3,561
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates31$2,048
Sucralfate41$1,851
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine74$1,843
Omeprazole91$1,777
CholestyramineCholestyramine (With Sugar)23$1,506
Dicyclomine Hcl60$1,498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$15$50,83017 claims
AbbVieLinzess$1,653$45,82345 claims
Redhill Biopharma Inc.Movantik$11$7,48219 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$394$6,03112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Federal Way

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →